Following the FDA approval of the groundbreaking pill Gilenya, a recent study has shown another oral medication may be beneficial to patients with multiple sclerosis (MS), according to WebMD News.

Research revealed in the New England Journal of Medicine this week has found that a new disease-modifying pill known as teriflunomide may  also inhibit the progression of MS, a neurological disorder that causes the degeneration of the brain’s protective layers (known as myelin sheaths). This is more good news for sufferers who have no choice but to endure intravenous treatments.

“Some patients have been sitting on the sidelines waiting for effective and safe oral medications,” Jerry S. Wolinsky, researcher and professor of neurology at the University of Texas Health Science Center, told the news source. “[Patients'] skin is just not holding up well. It’s harder and harder for me to convince them to keep doing [the injections] because of the difficulty they have.”

The success of teriflunomide is another milestone for the research of multiple sclerosis treatments, and there may be more on the horizon, as the FDA is reportedly reviewing three additional pills for MS patients.

Researchers analyzed patients with a form of the nervous disorder known as “relapsing remitting MS,” in which patients often have a “flare-up” before going into remission. Compared to placebo use, relapse rates in those taking teriflunomide daily were reduced by more than 30 percent.

“What it [means] to a patient is that if you were destined to have three attacks in one year, you would actually only have two,” Paul O’Connor, researcher and professor of neurology at the University of Toronto, told the news provider. “It slowed relapse and reduced the risk of disability progression.”